TENDER PAR-25-101
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
<p>The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant preceden
Tender details
- Reference
- PAR-25-101
- Issuing organisation
- Not recorded
- Opportunity type
- Grant opportunity
- Industry
- Other
- Location
- Not recorded
- Closing date
- 11 August 2027
- Document deadline
- Not stated
- Bid security
- Not stated
- Language
- en
- Source-reported status
- Posted (as of 18 November 2026)
- Status from closing date
- Open (11 August 2027)
Source excerpt
Open official sourceOpportunity number: PAR-25-101 Title: Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) Agency: National Institutes of Health Status: POSTED Posting date: 2024-12-30 Application response date: 2027-08-11 Description: <p>The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly in
Verified against the retrieved official source recorded as document DOC-US-0027. SHA-256 ee8d92c3fce534b5303b9f81ab3508942cd0bbd71116faf624fb206d3c8747b5 (checksum scope: source response).